APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Virus Like Particles

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Virus Like Particles Industry Growth and Trends Forecast to 2032

Report ID 174046540129 December 2025115 pages

Choose your research edition.

Industry ResearchVirus Like Particles Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Virus Like Particles Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Virus Like Particles Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Virus Like Particles Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Virus Like Particles Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Virus Like Particles market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Virus Like Particles is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Virus Like Particles is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Virus Like Particles is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Virus Like Particles include Agilvax, Allergy Therapeutics, ANGANY Genetics, CPL Biologicals, Cytos Biotechnology, GeoVax Labs, Medicago, MedImmune and Novavax, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Virus Like Particles market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Virus Like Particles market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Virus Like Particles market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Virus Like Particles.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Virus Like Particles market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Virus Like Particles Market by Company

Agilvax

Allergy Therapeutics

ANGANY Genetics

CPL Biologicals

Cytos Biotechnology

GeoVax Labs

Medicago

MedImmune

Novavax

Serum Institute of India

TechnoVax

Xiamen Innovax Biotech

GlaxoSmithKline

Merck

Takeda

Virus Like Particles Segment by Type

Hepatitis B Virus

Adeno-Associated Virus

Hepatitis C Virus

HIV

Others

Virus Like Particles Segment by Application

Therapeutic and Imaging Agents

Mycoviruses

Vaccines

Virus Research

Others

Virus Like Particles Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Virus Like Particles market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Virus Like Particles and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Virus Like Particles.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Virus Like Particles manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Virus Like Particles in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Hepatitis B Virus Table 2. Major Company of Adeno-Associated Virus Table 3. Major Company of Hepatitis C Virus Table 4. Major Company of HIV Table 5. Major Company of Others Table 6. Global Virus Like Particles Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Virus Like Particles Sales by Type (2021-2026) & (K Units) Table 8. Global Virus Like Particles Sales Market Share in Volume by Type (2021-2026) Table 9. Global Virus Like Particles Sales by Type (2021-2026) & (US$ Million) Table 10. Global Virus Like Particles Sales Market Share in Value by Type (2021-2026) Table 11. Global Virus Like Particles Price by Type (2021-2026) & (US$/Unit) Table 12. Global Virus Like Particles Sales by Type (2027-2032) & (K Units) Table 13. Global Virus Like Particles Sales Market Share in Volume by Type (2027-2032) Table 14. Global Virus Like Particles Sales by Type (2027-2032) & (US$ Million) Table 15. Global Virus Like Particles Sales Market Share in Value by Type (2027-2032) Table 16. Global Virus Like Particles Price by Type (2027-2032) & (US$/Unit) Table 17. North America Virus Like Particles Sales by Type (2021-2026) & (K Units) Table 18. North America Virus Like Particles Sales by Type (2021-2026) & (US$ Million) Table 19. Europe Virus Like Particles Sales by Type (2021-2026) & (K Units) Table 20. Europe Virus Like Particles Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific Virus Like Particles Sales by Type (2021-2026) & (K Units) Table 22. Asia-Pacific Virus Like Particles Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America Virus Like Particles Sales by Type (2021-2026) & (K Units) Table 24. Latin America Virus Like Particles Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa Virus Like Particles Sales by Type (2021-2026) & (K Units) Table 26. Middle East and Africa Virus Like Particles Sales by Type (2021-2026) & (US$ Million) Table 27. Virus Like Particles Industry Trends Table 28. Virus Like Particles Industry Drivers Table 29. Virus Like Particles Industry Opportunities and Challenges Table 30. Virus Like Particles Industry Restraints Table 31. Global Virus Like Particles Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global Virus Like Particles Revenue Market Share by Company (2021-2026) Table 33. Global Virus Like Particles Sales by Company (2021-2026) & (K Units) Table 34. Global Virus Like Particles Sales Share by Company (2021-2026) Table 35. Global Virus Like Particles Market Price by Company (2021-2026) & (US$/Unit) Table 36. Global Virus Like Particles Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global Virus Like Particles Major Company Production Sites and Headquarters Table 38. Global Virus Like Particles Company, Product Type & Application Table 39. Global Virus Like Particles Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global Virus Like Particles by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global Virus Like Particles Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global Virus Like Particles Sales by Region (2021-2026) & (K Units) Table 44. Global Virus Like Particles Sales Market Share in Volume by Region (2021-2026) Table 45. Global Virus Like Particles Sales by Region (2021-2026) & (US$ Million) Table 46. Global Virus Like Particles Sales Market Share in Value by Region (2021-2026) Table 47. Global Virus Like Particles Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 48. Global Virus Like Particles Sales by Region (2027-2032) & (K Units) Table 49. Global Virus Like Particles Sales Market Share in Volume by Region (2027-2032) Table 50. Global Virus Like Particles Sales by Region (2027-2032) & (US$ Million) Table 51. Global Virus Like Particles Sales Market Share in Value by Region (2027-2032) Table 52. Global Virus Like Particles Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 53. Global Virus Like Particles Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global Virus Like Particles Sales by Application (2021-2026) & (K Units) Table 55. Global Virus Like Particles Sales Market Share in Volume by Application (2021-2026) Table 56. Global Virus Like Particles Sales by Application (2021-2026) & (US$ Million) Table 57. Global Virus Like Particles Sales Market Share in Value by Application (2021-2026) Table 58. Global Virus Like Particles Price by Application (2021-2026) & (US$/Unit) Table 59. Global Virus Like Particles Sales by Application (2027-2032) & (K Units) Table 60. Global Virus Like Particles Sales Market Share in Volume by Application (2027-2032) Table 61. Global Virus Like Particles Sales by Application (2027-2032) & (US$ Million) Table 62. Global Virus Like Particles Sales Market Share in Value by Application (2027-2032) Table 63. Global Virus Like Particles Price by Application (2027-2032) & (US$/Unit) Table 64. North America Virus Like Particles Sales by Application (2021-2026) & (K Units) Table 65. North America Virus Like Particles Sales by Application (2021-2026) & (US$ Million) Table 66. Europe Virus Like Particles Sales by Application (2021-2026) & (K Units) Table 67. Europe Virus Like Particles Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific Virus Like Particles Sales by Application (2021-2026) & (K Units) Table 69. Asia-Pacific Virus Like Particles Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America Virus Like Particles Sales by Application (2021-2026) & (K Units) Table 71. Latin America Virus Like Particles Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa Virus Like Particles Sales by Application (2021-2026) & (K Units) Table 73. Middle East and Africa Virus Like Particles Sales by Application (2021-2026) & (US$ Million) Table 74. Agilvax Company Information Table 75. Agilvax Business Overview Table 76. Agilvax Virus Like Particles Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Agilvax Virus Like Particles Product Portfolio Table 78. Agilvax Recent Development Table 79. Allergy Therapeutics Company Information Table 80. Allergy Therapeutics Business Overview Table 81. Allergy Therapeutics Virus Like Particles Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Allergy Therapeutics Virus Like Particles Product Portfolio Table 83. Allergy Therapeutics Recent Development Table 84. ANGANY Genetics Company Information Table 85. ANGANY Genetics Business Overview Table 86. ANGANY Genetics Virus Like Particles Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. ANGANY Genetics Virus Like Particles Product Portfolio Table 88. ANGANY Genetics Recent Development Table 89. CPL Biologicals Company Information Table 90. CPL Biologicals Business Overview Table 91. CPL Biologicals Virus Like Particles Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. CPL Biologicals Virus Like Particles Product Portfolio Table 93. CPL Biologicals Recent Development Table 94. Cytos Biotechnology Company Information Table 95. Cytos Biotechnology Business Overview Table 96. Cytos Biotechnology Virus Like Particles Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Cytos Biotechnology Virus Like Particles Product Portfolio Table 98. Cytos Biotechnology Recent Development Table 99. GeoVax Labs Company Information Table 100. GeoVax Labs Business Overview Table 101. GeoVax Labs Virus Like Particles Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. GeoVax Labs Virus Like Particles Product Portfolio Table 103. GeoVax Labs Recent Development Table 104. Medicago Company Information Table 105. Medicago Business Overview Table 106. Medicago Virus Like Particles Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Medicago Virus Like Particles Product Portfolio Table 108. Medicago Recent Development Table 109. MedImmune Company Information Table 110. MedImmune Business Overview Table 111. MedImmune Virus Like Particles Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. MedImmune Virus Like Particles Product Portfolio Table 113. MedImmune Recent Development Table 114. Novavax Company Information Table 115. Novavax Business Overview Table 116. Novavax Virus Like Particles Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Novavax Virus Like Particles Product Portfolio Table 118. Novavax Recent Development Table 119. Serum Institute of India Company Information Table 120. Serum Institute of India Business Overview Table 121. Serum Institute of India Virus Like Particles Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Serum Institute of India Virus Like Particles Product Portfolio Table 123. Serum Institute of India Recent Development Table 124. TechnoVax Company Information Table 125. TechnoVax Business Overview Table 126. TechnoVax Virus Like Particles Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. TechnoVax Virus Like Particles Product Portfolio Table 128. TechnoVax Recent Development Table 129. Xiamen Innovax Biotech Company Information Table 130. Xiamen Innovax Biotech Business Overview Table 131. Xiamen Innovax Biotech Virus Like Particles Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Xiamen Innovax Biotech Virus Like Particles Product Portfolio Table 133. Xiamen Innovax Biotech Recent Development Table 134. GlaxoSmithKline Company Information Table 135. GlaxoSmithKline Business Overview Table 136. GlaxoSmithKline Virus Like Particles Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. GlaxoSmithKline Virus Like Particles Product Portfolio Table 138. GlaxoSmithKline Recent Development Table 139. Merck Company Information Table 140. Merck Business Overview Table 141. Merck Virus Like Particles Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Merck Virus Like Particles Product Portfolio Table 143. Merck Recent Development Table 144. Takeda Company Information Table 145. Takeda Business Overview Table 146. Takeda Virus Like Particles Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. Takeda Virus Like Particles Product Portfolio Table 148. Takeda Recent Development Table 149. North America Virus Like Particles Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 150. North America Virus Like Particles Sales by Country (2021-2026) & (K Units) Table 151. North America Virus Like Particles Sales Market Share by Country (2021-2026) Table 152. North America Virus Like Particles Sales Forecast by Country (2027-2032) & (K Units) Table 153. North America Virus Like Particles Sales Market Share Forecast by Country (2027-2032) Table 154. North America Virus Like Particles Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 155. North America Virus Like Particles Market Size by Country (2021-2026) & (US$ Million) Table 156. North America Virus Like Particles Market Share by Country (2021-2026) Table 157. North America Virus Like Particles Market Size Forecast by Country (2027-2032) & (US$ Million) Table 158. North America Virus Like Particles Market Share Forecast by Country (2027-2032) Table 159. Europe Virus Like Particles Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 160. Europe Virus Like Particles Sales by Country (2021-2026) & (K Units) Table 161. Europe Virus Like Particles Sales Market Share by Country (2021-2026) Table 162. Europe Virus Like Particles Sales Forecast by Country (2027-2032) & (K Units) Table 163. Europe Virus Like Particles Sales Market Share Forecast by Country (2027-2032) Table 164. Europe Virus Like Particles Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 165. Europe Virus Like Particles Market Size by Country (2021-2026) & (US$ Million) Table 166. Europe Virus Like Particles Market Share by Country (2021-2026) Table 167. Europe Virus Like Particles Market Size Forecast by Country (2027-2032) & (US$ Million) Table 168. Europe Virus Like Particles Market Share Forecast by Country (2027-2032) Table 169. Asia-Pacific Virus Like Particles Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 170. Asia-Pacific Virus Like Particles Sales by Country (2021-2026) & (K Units) Table 171. Asia-Pacific Virus Like Particles Sales Market Share by Country (2021-2026) Table 172. Asia-Pacific Virus Like Particles Sales Forecast by Country (2027-2032) & (K Units) Table 173. Asia-Pacific Virus Like Particles Sales Market Share Forecast by Country (2027-2032) Table 174. Asia-Pacific Virus Like Particles Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 175. Asia-Pacific Virus Like Particles Market Size by Country (2021-2026) & (US$ Million) Table 176. Asia-Pacific Virus Like Particles Market Share by Country (2021-2026) Table 177. Asia-Pacific Virus Like Particles Market Size Forecast by Country (2027-2032) & (US$ Million) Table 178. Asia-Pacific Virus Like Particles Market Share Forecast by Country (2027-2032) Table 179. Latin America Virus Like Particles Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 180. Latin America Virus Like Particles Sales by Country (2021-2026) & (K Units) Table 181. Latin America Virus Like Particles Sales Market Share by Country (2021-2026) Table 182. Latin America Virus Like Particles Sales Forecast by Country (2027-2032) & (K Units) Table 183. Latin America Virus Like Particles Sales Market Share Forecast by Country (2027-2032) Table 184. Latin America Virus Like Particles Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 185. Latin America Virus Like Particles Market Size by Country (2021-2026) & (US$ Million) Table 186. Latin America Virus Like Particles Market Share by Country (2021-2026) Table 187. Latin America Virus Like Particles Market Size Forecast by Country (2027-2032) & (US$ Million) Table 188. Latin America Virus Like Particles Market Share Forecast by Country (2027-2032) Table 189. Middle East and Africa Virus Like Particles Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 190. Middle East and Africa Virus Like Particles Sales by Country (2021-2026) & (K Units) Table 191. Middle East and Africa Virus Like Particles Sales Market Share by Country (2021-2026) Table 192. Middle East and Africa Virus Like Particles Sales Forecast by Country (2027-2032) & (K Units) Table 193. Middle East and Africa Virus Like Particles Sales Market Share Forecast by Country (2027-2032) Table 194. Middle East and Africa Virus Like Particles Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 195. Middle East and Africa Virus Like Particles Market Size by Country (2021-2026) & (US$ Million) Table 196. Middle East and Africa Virus Like Particles Market Share by Country (2021-2026) Table 197. Middle East and Africa Virus Like Particles Market Size Forecast by Country (2027-2032) & (US$ Million) Table 198. Middle East and Africa Virus Like Particles Market Share Forecast by Country (2027-2032) Table 199. Key Raw Materials Table 200. Raw Materials Key Suppliers Table 201. Virus Like Particles Distributors List Table 202. Virus Like Particles Customers List Table 203. Research Programs/Design for This Report Table 204. Authors List of This Report Table 205. Secondary Sources Table 206. Primary Sources List of Figures Figure 1. Virus Like Particles Image Figure 2. Global Virus Like Particles Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Virus Like Particles Market Size (2021-2032) & (US$ Million) Figure 4. Global Virus Like Particles Sales (2021-2032) & (K Units) Figure 5. Hepatitis B Virus Image Figure 6. Global Hepatitis B Virus Sales YoY Growth (2021-2032) & (K Units) Figure 7. Adeno-Associated Virus Image Figure 8. Global Adeno-Associated Virus Sales YoY Growth (2021-2032) & (K Units) Figure 9. Hepatitis C Virus Image Figure 10. Global Hepatitis C Virus Sales YoY Growth (2021-2032) & (K Units) Figure 11. HIV Image Figure 12. Global HIV Sales YoY Growth (2021-2032) & (K Units) Figure 13. Others Image Figure 14. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 15. Global Virus Like Particles Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global Virus Like Particles Market Share by Type 2025 VS 2032 Figure 17. North America Virus Like Particles Sales Market Share in Volume by Type in 2025 Figure 18. North America Virus Like Particles Sales Market Share in Value by Type in 2025 Figure 19. Europe Virus Like Particles Sales Market Share in Volume by Type in 2025 Figure 20. Europe Virus Like Particles Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific Virus Like Particles Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific Virus Like Particles Sales Market Share in Value by Type in 2025 Figure 23. Latin America Virus Like Particles Sales Market Share in Volume by Type in 2025 Figure 24. Latin America Virus Like Particles Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa Virus Like Particles Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa Virus Like Particles Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 Virus Like Particles Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Therapeutic and Imaging Agents Image Figure 30. Global Therapeutic and Imaging Agents Sales YoY Growth (2021-2032) & (K Units) Figure 31. Mycoviruses Image Figure 32. Global Mycoviruses Sales YoY Growth (2021-2032) & (K Units) Figure 33. Vaccines Image Figure 34. Global Vaccines Sales YoY Growth (2021-2032) & (K Units) Figure 35. Virus Research Image Figure 36. Global Virus Research Sales YoY Growth (2021-2032) & (K Units) Figure 37. Others Image Figure 38. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 39. Global Virus Like Particles Market Size Overview by Application (2021-2032) & (US$ Million) Figure 40. Global Virus Like Particles Market Share by Application 2025 VS 2032 Figure 41. North America Virus Like Particles Sales Market Share in Volume by Application in 2025 Figure 42. North America Virus Like Particles Sales Market Share in Value by Application in 2025 Figure 43. Europe Virus Like Particles Sales Market Share in Volume by Application in 2025 Figure 44. Europe Virus Like Particles Sales Market Share in Value by Application in 2025 Figure 45. Asia-Pacific Virus Like Particles Sales Market Share in Volume by Application in 2025 Figure 46. Asia-Pacific Virus Like Particles Sales Market Share in Value by Application in 2025 Figure 47. Latin America Virus Like Particles Sales Market Share in Volume by Application in 2025 Figure 48. Latin America Virus Like Particles Sales Market Share in Value by Application in 2025 Figure 49. Middle East and Africa Virus Like Particles Sales Market Share in Volume by Application in 2025 Figure 50. Middle East and Africa Virus Like Particles Sales Market Share in Value by Application in 2025 Figure 51. North America Virus Like Particles Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. North America Virus Like Particles Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. North America Virus Like Particles Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. North America Virus Like Particles Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Virus Like Particles Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Europe Virus Like Particles Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Europe Virus Like Particles Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Europe Virus Like Particles Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Virus Like Particles Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Asia-Pacific Virus Like Particles Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Virus Like Particles Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Asia-Pacific Virus Like Particles Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Virus Like Particles Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Latin America Virus Like Particles Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Latin America Virus Like Particles Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Latin America Virus Like Particles Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Virus Like Particles Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 68. Middle East and Africa Virus Like Particles Sales Share by Country: 2021 VS 2025 VS 2032 Figure 69. Middle East and Africa Virus Like Particles Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 70. Middle East and Africa Virus Like Particles Market Share by Country: 2021 VS 2025 VS 2032 Figure 71. Virus Like Particles Value Chain Figure 72. Key Raw Materials Price Figure 73. Manufacturing Cost Structure Figure 74. Virus Like Particles Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • Hepatitis B Virus
  • Adeno-Associated Virus
  • Hepatitis C Virus
  • HIV
  • Others
Applications
  • Therapeutic and Imaging Agents
  • Mycoviruses
  • Vaccines
  • Virus Research
  • Others
Companies covered
  • Agilvax
  • Allergy Therapeutics
  • ANGANY Genetics
  • CPL Biologicals
  • Cytos Biotechnology
  • GeoVax Labs
  • Medicago
  • MedImmune
  • Novavax
  • Serum Institute of India
  • TechnoVax
  • Xiamen Innovax Biotech
  • GlaxoSmithKline
  • Merck
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Virus Like Particles Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Virus Like Particles Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Virus Like Particles Market by Type
  6. 1.3.1 Hepatitis B Virus
  7. 1.3.2 Adeno-Associated Virus
  8. 1.3.3 Hepatitis C Virus
  9. 1.3.4 HIV
  10. 1.3.5 Others
  11. 1.4 Global Virus Like Particles Market Size by Type
  12. 1.4.1 Global Virus Like Particles Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global Virus Like Particles Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global Virus Like Particles Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America Virus Like Particles Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe Virus Like Particles Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific Virus Like Particles Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America Virus Like Particles Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa Virus Like Particles Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Virus Like Particles Industry Trends
  2. 2.2 Virus Like Particles Industry Drivers
  3. 2.3 Virus Like Particles Industry Opportunities and Challenges
  4. 2.4 Virus Like Particles Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Virus Like Particles Revenue (2021-2026)
  2. 3.2 Global Top Players by Virus Like Particles Sales (2021-2026)
  3. 3.3 Global Top Players by Virus Like Particles Price (2021-2026)
  4. 3.4 Global Virus Like Particles Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Virus Like Particles Major Company Production Sites & Headquarters
  6. 3.6 Global Virus Like Particles Company, Product Type & Application
  7. 3.7 Global Virus Like Particles Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Virus Like Particles Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Virus Like Particles Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Virus Like Particles Tier 1, Tier 2, and Tier 3
4 Virus Like Particles Regional Status and Outlook
  1. 4.1 Global Virus Like Particles Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Virus Like Particles Historic Market Size by Region
  3. 4.2.1 Global Virus Like Particles Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Virus Like Particles Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Virus Like Particles Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Virus Like Particles Forecasted Market Size by Region
  7. 4.3.1 Global Virus Like Particles Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Virus Like Particles Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Virus Like Particles Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Virus Like Particles by Application
  1. 5.1 Virus Like Particles Market by Application
  2. 5.1.1 Therapeutic and Imaging Agents
  3. 5.1.2 Mycoviruses
  4. 5.1.3 Vaccines
  5. 5.1.4 Virus Research
  6. 5.1.5 Others
  7. 5.2 Global Virus Like Particles Market Size by Application
  8. 5.2.1 Global Virus Like Particles Market Size Overview by Application (2021-2032)
  9. 5.2.2 Global Virus Like Particles Historic Market Size Review by Application (2021-2026)
  10. 5.2.3 Global Virus Like Particles Forecasted Market Size by Application (2027-2032)
  11. 5.3 Key Regions Market Size by Application
  12. 5.3.1 North America Virus Like Particles Sales Breakdown by Application (2021-2026)
  13. 5.3.2 Europe Virus Like Particles Sales Breakdown by Application (2021-2026)
  14. 5.3.3 Asia-Pacific Virus Like Particles Sales Breakdown by Application (2021-2026)
  15. 5.3.4 South America Virus Like Particles Sales Breakdown by Application (2021-2026)
  16. 5.3.5 Middle East and Africa Virus Like Particles Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Agilvax
  2. 6.1.1 Agilvax Company Information
  3. 6.1.2 Agilvax Business Overview
  4. 6.1.3 Agilvax Virus Like Particles Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Agilvax Virus Like Particles Product Portfolio
  6. 6.1.5 Agilvax Recent Developments
  7. 6.2 Allergy Therapeutics
  8. 6.2.1 Allergy Therapeutics Company Information
  9. 6.2.2 Allergy Therapeutics Business Overview
  10. 6.2.3 Allergy Therapeutics Virus Like Particles Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Allergy Therapeutics Virus Like Particles Product Portfolio
  12. 6.2.5 Allergy Therapeutics Recent Developments
  13. 6.3 ANGANY Genetics
  14. 6.3.1 ANGANY Genetics Company Information
  15. 6.3.2 ANGANY Genetics Business Overview
  16. 6.3.3 ANGANY Genetics Virus Like Particles Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 ANGANY Genetics Virus Like Particles Product Portfolio
  18. 6.3.5 ANGANY Genetics Recent Developments
  19. 6.4 CPL Biologicals
  20. 6.4.1 CPL Biologicals Company Information
  21. 6.4.2 CPL Biologicals Business Overview
  22. 6.4.3 CPL Biologicals Virus Like Particles Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 CPL Biologicals Virus Like Particles Product Portfolio
  24. 6.4.5 CPL Biologicals Recent Developments
  25. 6.5 Cytos Biotechnology
  26. 6.5.1 Cytos Biotechnology Company Information
  27. 6.5.2 Cytos Biotechnology Business Overview
  28. 6.5.3 Cytos Biotechnology Virus Like Particles Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Cytos Biotechnology Virus Like Particles Product Portfolio
  30. 6.5.5 Cytos Biotechnology Recent Developments
  31. 6.6 GeoVax Labs
  32. 6.6.1 GeoVax Labs Company Information
  33. 6.6.2 GeoVax Labs Business Overview
  34. 6.6.3 GeoVax Labs Virus Like Particles Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 GeoVax Labs Virus Like Particles Product Portfolio
  36. 6.6.5 GeoVax Labs Recent Developments
  37. 6.7 Medicago
  38. 6.7.1 Medicago Company Information
  39. 6.7.2 Medicago Business Overview
  40. 6.7.3 Medicago Virus Like Particles Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Medicago Virus Like Particles Product Portfolio
  42. 6.7.5 Medicago Recent Developments
  43. 6.8 MedImmune
  44. 6.8.1 MedImmune Company Information
  45. 6.8.2 MedImmune Business Overview
  46. 6.8.3 MedImmune Virus Like Particles Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 MedImmune Virus Like Particles Product Portfolio
  48. 6.8.5 MedImmune Recent Developments
  49. 6.9 Novavax
  50. 6.9.1 Novavax Company Information
  51. 6.9.2 Novavax Business Overview
  52. 6.9.3 Novavax Virus Like Particles Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Novavax Virus Like Particles Product Portfolio
  54. 6.9.5 Novavax Recent Developments
  55. 6.10 Serum Institute of India
  56. 6.10.1 Serum Institute of India Company Information
  57. 6.10.2 Serum Institute of India Business Overview
  58. 6.10.3 Serum Institute of India Virus Like Particles Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Serum Institute of India Virus Like Particles Product Portfolio
  60. 6.10.5 Serum Institute of India Recent Developments
  61. 6.11 TechnoVax
  62. 6.11.1 TechnoVax Company Information
  63. 6.11.2 TechnoVax Business Overview
  64. 6.11.3 TechnoVax Virus Like Particles Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 TechnoVax Virus Like Particles Product Portfolio
  66. 6.11.5 TechnoVax Recent Developments
  67. 6.12 Xiamen Innovax Biotech
  68. 6.12.1 Xiamen Innovax Biotech Company Information
  69. 6.12.2 Xiamen Innovax Biotech Business Overview
  70. 6.12.3 Xiamen Innovax Biotech Virus Like Particles Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Xiamen Innovax Biotech Virus Like Particles Product Portfolio
  72. 6.12.5 Xiamen Innovax Biotech Recent Developments
  73. 6.13 GlaxoSmithKline
  74. 6.13.1 GlaxoSmithKline Company Information
  75. 6.13.2 GlaxoSmithKline Business Overview
  76. 6.13.3 GlaxoSmithKline Virus Like Particles Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 GlaxoSmithKline Virus Like Particles Product Portfolio
  78. 6.13.5 GlaxoSmithKline Recent Developments
  79. 6.14 Merck
  80. 6.14.1 Merck Company Information
  81. 6.14.2 Merck Business Overview
  82. 6.14.3 Merck Virus Like Particles Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Merck Virus Like Particles Product Portfolio
  84. 6.14.5 Merck Recent Developments
  85. 6.15 Takeda
  86. 6.15.1 Takeda Company Information
  87. 6.15.2 Takeda Business Overview
  88. 6.15.3 Takeda Virus Like Particles Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Takeda Virus Like Particles Product Portfolio
  90. 6.15.5 Takeda Recent Developments
7 North America by Country
  1. 7.1 North America Virus Like Particles Sales by Country
  2. 7.1.1 North America Virus Like Particles Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Virus Like Particles Sales by Country (2021-2026)
  4. 7.1.3 North America Virus Like Particles Sales Forecast by Country (2027-2032)
  5. 7.2 North America Virus Like Particles Market Size by Country
  6. 7.2.1 North America Virus Like Particles Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Virus Like Particles Market Size by Country (2021-2026)
  8. 7.2.3 North America Virus Like Particles Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Virus Like Particles Sales by Country
  2. 8.1.1 Europe Virus Like Particles Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Virus Like Particles Sales by Country (2021-2026)
  4. 8.1.3 Europe Virus Like Particles Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Virus Like Particles Market Size by Country
  6. 8.2.1 Europe Virus Like Particles Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Virus Like Particles Market Size by Country (2021-2026)
  8. 8.2.3 Europe Virus Like Particles Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Virus Like Particles Sales by Country
  2. 9.1.1 Asia-Pacific Virus Like Particles Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Virus Like Particles Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Virus Like Particles Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Virus Like Particles Market Size by Country
  6. 9.2.1 Asia-Pacific Virus Like Particles Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Virus Like Particles Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Virus Like Particles Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Virus Like Particles Sales by Country
  2. 10.1.1 South America Virus Like Particles Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Virus Like Particles Sales by Country (2021-2026)
  4. 10.1.3 South America Virus Like Particles Sales Forecast by Country (2027-2032)
  5. 10.2 South America Virus Like Particles Market Size by Country
  6. 10.2.1 South America Virus Like Particles Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Virus Like Particles Market Size by Country (2021-2026)
  8. 10.2.3 South America Virus Like Particles Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Virus Like Particles Sales by Country
  2. 11.1.1 Middle East and Africa Virus Like Particles Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Virus Like Particles Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Virus Like Particles Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Virus Like Particles Market Size by Country
  6. 11.2.1 Middle East and Africa Virus Like Particles Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Virus Like Particles Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Virus Like Particles Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Virus Like Particles Value Chain Analysis
  2. 12.1.1 Virus Like Particles Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Virus Like Particles Production Mode & Process
  7. 12.2 Virus Like Particles Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Virus Like Particles Distributors
  10. 12.2.3 Virus Like Particles Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst